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Pseudo-Pseudotumor: A Cautionary Tale
Brian Westerhuis and Sachin Kedar

Mentor: Sachin Kedar
Program: Neurology
Background: Idiopathic Intracranial
Hypertension (IIH) is a commonly considered
diagnosis and common reason for neurology
consultation.
Methodology: Case series
Results: Two cases of presumed IIH presented
with progressively worsening headache and
reduced vision. Both had papilledema on
exam and elevated CSF opening pressures
on lumbar puncture. CSF contents were
normal. In one, initial imaging (MRI brain)

revealed the “partially empty sella” raising
concern for IIH. In the other, imaging was
initially unrevealing. Both were started on
Acetazolamide for presumed IIH. Both
patients experienced progressive deterioration
of vision, papilledema and headache. The
first patient was found to have extensive
cerebral venous sinus thrombosis and started
on anticoagulation. The second patient was
found to have leptomeningeal glioma after
several months and started on chemotherapy.
Guidelines and recommendations for
evaluating these patients are reviewed

cerebral venous sinus thrombosis and
intracranial malignancies. “Pseudotumor
cerebri” remains a diagnosis of exclusion,
particularly in patients who do not fit the
“classic” phenotype. There is a very real
danger in prematurely closing on the diagnosis
without sufficient investigation to rule out
other causes. A high index of suspicion for
an alternate diagnosis must remain until
sufficient investigation is completed. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.068

Conclusion: Numerous processes produce
elevated intracranial pressure, including

Evaluation of a Midline Catheter Program and Effect on Central Line Associated Blood Stream Infections
Richard Hankins, Mark Rupp, Teresa Micheels, Luana Evans, Angela Boesch, Kim Hayes, Adrienne Sy, Kelly Cawcutt

Mentor: Kelly Cawcutt
Program: Infectious Disease
Background: Central line associated
blood stream infections (CLABSI) result
in increased patient morbidity. Guidelines
recommend against peripheral venous
catheters when access is required for longer
than 6 days, leading to central venous catheter
(CVCs) placement. To improve vascular
access device choice, we implemented a
quality improvement initiative compromised
of a new vascular access algorithm with
introduction of midline utilization and sought
to evaluate the impact of midline use on
CLABSI rates.

Methods: A prospective quality improvement
assessment from October 2017 through
March 2018 analyzed vascular access. When
a consult was placed for a peripherally
inserted central catheter (PICC) a patient
would be evaluated via the vascular access
algorithm for whether they should receive
a midline catheter, a PICC or CVC. They
were then monitored for duration of indwell
and bloodstream infections consistent with
reportable CLABSI definitions.
Results: In the month prior to
implementation, the institutional CLABSI
rate was 1.36 per 1000 CVC (including PICC)
days. Since October 2017, there have been
4588 midline catheter days, with 2 midline

infections, for a cumulative rate over 6
months of 0.435 midline catheter infections
per 1000 midline days. This was compared
to 26,575 CVC days, with 33 documented
CLABSIs, for a rate of 1.242 per 1000 CVC
days.
Conclusion: The implementation of a
vascular access algorithm including midlines
may reduce central line insertions and
decrease CLABSIs through utilization of a
lower risk device (midline). Further research
into comparing additional risks and benefits
of midline catheters and all styles of central
venous catheters is warranted. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.069

Left Ventricular Assist Device (LVAD) Infections: A Single Center Experience
Rajendra Karnatak, Uriel Sadkovsky

Mentor: Uriel Sadkovsky
Program: Infectious Disease
Background: Infectious complications play a
major role in morbidity LVAD implantation.
We report the incidence of LVAD infections at
our institution over 1-year period.
Methods: Retrospective review of 36 patients
who had a continuous-flow LVAD implanted
between Jan 1-Dec 31, 2013. Infectious
complications were defined as per ISHLT
standardized definition. Only patients with
a new LVAD were included. Follow-up
occurred until heart transplantation or death.
Results: All patients underwent Heartmate
II implantation; 55% received the LVAD as
bridge to transplantation. We identified 39
episodes of infection in 20 (55%) patients.
Mean age (±SD) 52±15 years. A total of
19175 person-days of LVAD support was

followed, and average duration of LVAD
support was 533 days. There were 11 (25%)
driveline infections, 9 (21%) bloodstream
infections. The most common microorganism causing bloodstream infections
were coagulase negative staphylococci
4/9 (44%), followed by Staphylococcus
aureus 2/9 (22%), Enterococci 1/9 (11%),
Streptococci 1/9 (11%), and Candida 1/9
(11%). Table 1 summarizes incidence of
LVAD infections cases per 100-person years
of LVAD support as per ISHLT definition.
Two patients (6%) developed VAD-specific
cannula/pump infections, one treated with
Intravenous antibiotics followed by heart
transplantation, and one required long-term
antibiotic suppression. Cumulative all-cause
mortality at two years follow up was 19%.
Two-year cumulative all-cause mortality in
patients with LVAD infections was lower than
patients without infections 15% versus 25%
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(RR 0.6, 95% CI 0.15 to 2.3), respectively.
There were 8 (22%) patients treated for
an infection within 30 days prior to LVAD
implantation, out of these 4 developed post
LVAD infections, 4 did not develop infectious
complications (20% vs 25% RR 0.8, 95% CI
0.23 TO 2.7), respectively. The most common
cause of death was withdrawal of support/
multi-organ failure, 4 patients (57%). Only
1/7 (14.2%) deaths during two-year period
were due to infectious complications.
Conclusion: Morbidity in LVAD recipients is
primarily driven by driveline infections and
bacteremia. Infectious complications were not
associated with increased mortality. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.070
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